title: Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.
abstract: Recent reports have shown that phosphodiesterase (PDE) inhibitors suppress production of tumour necrosis factor-alpha (TNF-alpha) in mouse macrophages. In the present study we show that theophylline, pentoxifylline and 3-isobutyl-1-methylxanthine markedly suppress the lipopolysaccharide (LPS)-induced synthesis of TNF-alpha (also) in human mononuclear cells. This effect is selective for TNF-alpha since up to several-fold higher concentrations of these PDE inhibitors do not affect production of interleukin-1 beta (IL-1 beta) in the same system. The observed effect of PDE inhibitors appears to be mediated by accumulation of cAMP since (i) addition of PDE inhibitors increases cAMP while cGMP levels are only marginally elevated; (ii) raising cAMP by another mechanism (enhanced formation induced by prostaglandin E2; PGE2) leads to a similar suppression of TNF-alpha production; and (iii) raising cGMP by activating the soluble guanylate cyclase by 3-morpholinosydnonimine (SIN 1) does not inhibit TNF-alpha synthesis. However, SIN 1 suppressed the synthesis of IL-1 beta. Selective suppression of TNF-alpha synthesis by PDE inhibitors may contribute to their beneficial effects in animal models of septic shock or lung injury and may thus have clinical implications.
authors.affiliation: Medizinische Klinik, Klinikum Innenstadt, Universität München, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Endres
authors.forename: H J
authors.initials: HJ
authors.lastname: Fülle
authors.forename: B
authors.initials: B
authors.lastname: Sinha
authors.forename: D
authors.initials: D
authors.lastname: Stoll
authors.forename: C A
authors.initials: CA
authors.lastname: Dinarello
authors.forename: R
authors.initials: R
authors.lastname: Gerzer
authors.forename: P C
authors.initials: PC
authors.lastname: Weber
mesh_terms: D002460:Cell Line; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D015232:Dinoprostone / Q000494:pharmacology; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis*; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008070:Lipopolysaccharides / Q000276:immunology; D009000:Monocytes / Q000276:immunology; D009712:Nucleotides, Cyclic / Q000502:physiology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
chemical_list: D007375:Interleukin-1; D008070:Lipopolysaccharides; D009712:Nucleotides, Cyclic; D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D000242:Cyclic AMP; D006152:Cyclic GMP; D015232:Dinoprostone